Characterization of serum HER2 ECD level in patients with metastatic colorectal cancer

被引：0
|
作者：
Taniguchi, H. [1 ]
Hasegawa, H. [2 ]
Masuishi, T. [1 ]
Narita, Y. [1 ]
Komori, A. [1 ]
Kadowaki, S. [1 ]
Ura, T. [3 ]
Muro, K. [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[2] Osaka Natl Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[3] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv233.229
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-232
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Serum HER2/neu levels in breast cancer patients with different level of tumor HER2/neu protein expression
    Kushlinsky, Nicolai
    Gershtein, Elena
    Shyroky, Vyacheslav
    Ermilova, Valeriya
    Tchemeris, Galina
    Letyagin, Victor
    TUMOR BIOLOGY, 2007, 28 : 95 - 95
  • [32] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
  • [33] High serum YKL-40, but not plasma VEGF and serum HER2, as a prognostic biomarker of short survival in patients with metastatic colorectal cancer
    Nicolaisen, N.
    Johansen, J. S.
    Pfeiffer, P.
    Christensen, I. J.
    Qvortrup, C.
    Nielsen, S. E.
    Glimelius, B.
    Keldsen, N.
    Fokstuen, T.
    Jensen, B. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Influence of HER2 Overexpression on Response to Cetuximab in Patients with Metastatic Colorectal Cancer, Tehran, Iran
    Mozafari, Rambod
    Emami, Amir Hossein
    Nodehi, Sayyed Reza Safaee
    Shahi, Farhad
    Zebardast, Jayran
    Seyedalinaghi, SeyedAhmad
    Asadollahi-Amin, Ali
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2018, 6 (02): : 57 - 63
  • [35] The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.
    Kong, SY
    Kwon, Y
    Lee, DH
    Lee, JS
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 48S - 48S
  • [36] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
    Perik, Patrick J.
    Lub-de Hogge, Marjolijn N.
    Gietema, Jourik A.
    Jager, Piet L.
    Kosterink, Jos G.
    de Korte, Sander A.
    van Veldhuisen, Drik J.
    van der Graaf, Winette T.
    Sieijfer, Drik T.
    de Vries, Elisabeth G.
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [37] Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
    Jun Zhou
    Zhi Peng
    Yi Liu
    Jifang Gong
    Xiaotian Zhang
    Ming Lu
    Jing Gao
    Yili Li
    Yanyan Li
    Lin Shen
    Journal of Gastroenterology, 2015, 50 : 955 - 961
  • [38] Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
    Zhou, Jun
    Peng, Zhi
    Liu, Yi
    Gong, Jifang
    Zhang, Xiaotian
    Lu, Ming
    Gao, Jing
    Li, Yili
    Li, Yanyan
    Shen, Lin
    JOURNAL OF GASTROENTEROLOGY, 2015, 50 (09) : 955 - 961
  • [39] Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
    Olson, E. M.
    Flores, L. M.
    Najita, J. S.
    Curley, C.
    Jeong, J.
    Murray, K.
    Savoie, J. J.
    Winer, E. P.
    Krop, I. E.
    CANCER RESEARCH, 2011, 71
  • [40] Changes of serum HER2 status during clinical course of metastatic breast cancer patients
    Fehm, T
    Jäger, W
    Kraemer, S
    Sohn, C
    Solomayer-Meyberg, G
    Solomayer, EF
    Kurek, R
    Wallwiener, D
    Gebauer, G
    ANTICANCER RESEARCH, 2004, 24 (06) : 4205 - 4210
12345